Categories: Analysts

Buy Espial ahead of Q3 results, says Clarus analyst Ofir

Espial CEO Jaison Dolvane.
The recent pullback in shares of Espial Group (TSX:ESP) is a buying opportunity, says Clarus analyst Eyal Ofir.

In a research update to clients this morning, Ofir reiterated his “Buy” rating and $4.00 one-year target price on Espial, implying a return of 108.3% at the time of publication.

Ofir says shares of Espial has been hit with a double whammy that has left the stock about 40% off its 52-week highs. In August, he notes, the company’s stock fell after Rogers and Shaw announced a new Over the Top (OTT) video service called Shomi. That downtick bled into into the current market malaise.

The analyst says he thinks the initial pullback was unwarranted and that recent announcements from CBS and HBO about their new OTT services “highlight the urgent need for operators to migrate to next generation set-top-box (STB) platforms, specifically RDK, in order to keep pace with these emerging trends”.

Ofir says Espial has a solid client base of recurring revenue, a strong pipeline of opportunities with tier-one operators, is profitable and has a strong balance sheet. For these reasons, he sees the company’s current shares price as a “significant buying opportunity”.

The analyst expects Espial will post adjusted EPS of $0.01 on a topine of $4.5-million in its third quarter, which it will report on Wednesday. His target, he says, is based on 16x his expectation of the company’s fiscal 2015 earnings.

Tagged with: esp
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Acumen Capital likes NeuPath Health right now

Acumen Capital analyst Nick Corcoran has initiated coverage of NeuPath Health (NeuPath Health Stock Quote, Chart, News, Analysts, Financials TSXV:NPTH)… [Read More]

5 hours ago

CIBC just raised its price target on Celestica

In an April 14 note, CIBC World Markets analyst Todd Coupland said he expects Celestica (Celestica Stock Quote, Chart, News,… [Read More]

5 hours ago

Amazon’s grand ambitions are now in full view, this analyst says

Roth Capital Markets analyst Rohit Kulkarni maintained his “Buy” rating and $285.00 target on Amazon (Amazon Stock Quote, Chart, News,… [Read More]

6 hours ago

This analyst just upgraded Quebecor

National Bank Financial analyst Adam Shine upgraded Quebecor (Quebecor Stock Quote, Chart, News, Analysts, Financials TSX:QBR.B) to “Outperform” from “Sector… [Read More]

6 hours ago

Sell Cogeco? Here’s what this analyst says

RBC Capital Markets analyst Drew McReynolds cut his target on Cogeco Communications (Cogeco Communications Stock Quote, Chart, News, Analysts, Financials… [Read More]

11 hours ago

CoreWeave is a stock for the long haul, this analyst says

Roth Capital Markets analyst Rohit Kulkarni raised his target on CoreWeave (CoreWeave Stock Quote, Chart, News, Analysts, Financials NASDAQ:CRWV) to… [Read More]

11 hours ago